368.46
1.38%
+5.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché WST Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$363.43
Aprire:
$365.66
Volume 24 ore:
437.97K
Capitalizzazione di mercato:
$26.84B
Reddito:
$2.93B
Utile/perdita netta:
$568.70M
Rapporto P/E:
49.72
EPS:
7.41
Flusso di cassa netto:
$386.10M
1 W Prestazione:
+0.08%
1M Prestazione:
-5.01%
6M Prestazione:
+12.42%
1 anno Prestazione:
-0.31%
West Pharmaceutical Services, Inc. Stock (WST) Company Profile
Nome
West Pharmaceutical Services, Inc.
Settore
Industria
Telefono
610-594-2900
Indirizzo
530 Herman O. West Drive, Exton, PA
West Pharmaceutical Services, Inc. Stock (WST) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
2023-06-16 | Aggiornamento | BofA Securities | Neutral → Buy |
2023-04-11 | Aggiornamento | Stephens | Equal-Weight → Overweight |
2022-12-14 | Iniziato | Deutsche Bank | Hold |
2022-11-30 | Iniziato | UBS | Neutral |
2022-10-28 | Downgrade | BofA Securities | Buy → Neutral |
2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
2020-10-14 | Iniziato | Stephens | Equal-Weight |
2020-07-21 | Aggiornamento | BofA Securities | Neutral → Buy |
2020-04-24 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
2019-12-12 | Downgrade | BofA/Merrill | Neutral → Underperform |
2019-07-26 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
2019-05-01 | Downgrade | Jefferies | Buy → Hold |
2019-04-23 | Iniziato | William Blair | Outperform |
2018-04-25 | Downgrade | BofA/Merrill | Neutral → Underperform |
2018-01-24 | Iniziato | Goldman | Neutral |
2017-10-17 | Downgrade | BofA/Merrill | Buy → Neutral |
2017-10-03 | Iniziato | Stephens | Equal-Weight |
2017-09-15 | Aggiornamento | Jefferies | Hold → Buy |
2016-10-28 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
2016-09-21 | Downgrade | Wells Fargo | Outperform → Market Perform |
2016-03-22 | Iniziato | Wells Fargo | Outperform |
2010-05-14 | Reiterato | UBS | Neutral |
2010-02-23 | Iniziato | Jefferies & Co | Buy |
2008-12-19 | Iniziato | UBS | Neutral |
Mostra tutto
West Pharmaceutical Services, Inc. Borsa (WST) Ultime notizie
West Pharmaceutical (WST) Q1 Earnings Beat, HVP Sales Weak
Zacks Investment Research
West Pharmaceutical Services (WST) Tops Q1 Earnings and Revenue Estimates
Zacks Investment Research
Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates
Zacks Investment Research
Will West Pharmaceutical (WST) Beat Estimates Again in Its Next Earnings Report?
Zacks Investment Research
Is a Beat Likely for West Pharmaceutical (WST) in Q1 Earnings?
Zacks Investment Research
West Pharmaceutical Services (WST) Expected to Beat Earnings Estimates: Should You Buy?
Zacks Investment Research
West Pharmaceutical Services, Inc. Azioni (WST) Dati Finanziari
West Pharmaceutical Services, Inc. (WST) Reddito 2024
WST ha riportato un ricavo (TTM) di $2.93 miliardi per il trimestre terminato il 2024-03-31, un +1.56% salita anno su anno.
West Pharmaceutical Services, Inc. (WST) Reddito netto 2024
WST l'utile netto (TTM) è stato di $568.70 milioni per il trimestre terminato il 2024-03-31, un +3.01% aumento anno su anno.
West Pharmaceutical Services, Inc. (WST) Flusso di cassa 2024
WST ha registrato un flusso di cassa disponibile (TTM) di $386.10 milioni per il trimestre conclusosi con 2024-03-31, un -5.83% diminuire anno su anno.
West Pharmaceutical Services, Inc. (WST) Utile per azione 2024
L'utile per azione (TTM) di WST è stato pari a $7.58 per il trimestre terminato il 2024-03-31, un +4.12% crescita anno su anno.
West Pharmaceutical Services, Inc. Azioni (WST) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Winters Chad | VP, Chief Accounting Officer |
Mar 11 '24 |
Option Exercise |
173.22 |
675 |
116,924 |
2,124 |
Winters Chad | VP, Chief Accounting Officer |
Mar 11 '24 |
Sale |
358.82 |
815 |
292,436 |
1,309 |
Witherspoon Charles | VP & Treasurer |
Feb 28 '24 |
Option Exercise |
102.51 |
2,019 |
206,968 |
3,998 |
Witherspoon Charles | VP & Treasurer |
Feb 28 '24 |
Sale |
358.62 |
2,019 |
724,061 |
1,979 |
Green Eric Mark | President, CEO and Board Chair |
Feb 27 '24 |
Option Exercise |
57.38 |
73,132 |
4,196,314 |
217,040 |
Green Eric Mark | President, CEO and Board Chair |
Feb 27 '24 |
Sale |
359.85 |
64,132 |
23,077,971 |
152,908 |
Abraham Silji | SVP, Chief Technology Officer |
Feb 23 '24 |
Option Exercise |
173.22 |
7,012 |
1,214,619 |
11,672 |
Abraham Silji | SVP, Chief Technology Officer |
Feb 23 '24 |
Sale |
365.00 |
7,012 |
2,559,380 |
4,660 |
Winters Chad | VP, Chief Accounting Officer |
Dec 01 '23 |
Option Exercise |
156.18 |
797 |
124,472 |
2,283 |
Winters Chad | VP, Chief Accounting Officer |
Dec 01 '23 |
Sale |
349.00 |
1,013 |
353,541 |
1,270 |
Capitalizzazione:
|
Volume (24 ore):